FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028697269> ?p ?o ?g. }

• W2028697269 abstract "A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the combination of vinorelbine and capecitabine in patients affected with metastatic breast cancer. Eighteen patients with histologically confirmed advanced breast cancer, who had failed =1 prior chemotherapy regimen, were enrolled. The median age was 56 years (range, 39-70 years). All but 1 had previously received a combination of anthracyclines and taxanes; performance status (Eastern Cooperative Oncology Group) was 0/1 or 2 in 13 and 5 patients, respectively. Vinorelbine was administered at a fixed dosage of 25 mg/m2 on days 1 and 8 every 3 weeks. Capecitabine was administered orally, at an escalated dose ranging from 1400 mg/m2 to 2250 mg/m2 for 14 consecutive days starting on day 1 of the cycle, divided into 2 daily doses delivered half an hour after eating at 12-hour intervals. Three patients were treated at each dose level: if 1 patient developed a DLT, an additional 3 patients were treated at the same dose level. If 2 additional patients experienced DLT, no further escalation was allowed and the previous dose level was declared MTD. Dose-limiting toxicity was reached at 2250 mg/m2 of capecitabine with 3 out of 3 patients experiencing grade 4 neutropenia plus grade 3 diarrhea and grade 3 oral mucositis in 1 patient). Thus, MTD was defined at 2000 mg/m2 capecitabine. Other observed grade 2 side effects were: 1 patient with neutropenia, 1 with hand-foot syndrome, 2 with mucositis, 1 with cutaneous rash, and 1 with thrombocytopenia. With regard to response rate, we observed 1 complete response (5.5%), 6 partial responses (33%), and 4 disease stabilizations (22%). The median time to progression was 12 weeks and the median survival 41 weeks. The MTD of capecitabine in combination with vinorelbine at 25 mg/m2 dosage on days 1 and 8 of a 3-week schedule is 2000 mg/m2/day for 14 consecutive days. Moreover, this regimen showed interesting activity with 61% overall disease control (complete plus partial response plus disease stabilization) in patients pretreated with anthracyclines and taxanes warranting further investigations in a large, multicenter phase II study." @default.
• W2028697269 created "2016-06-24" @default.
• W2028697269 creator A5041259750 @default.
• W2028697269 creator A5051722602 @default.
• W2028697269 creator A5057828080 @default.
• W2028697269 creator A5059974723 @default.
• W2028697269 creator A5065513710 @default.
• W2028697269 creator A5086984759 @default.
• W2028697269 creator A5090055323 @default.
• W2028697269 date "2003-06-01" @default.
• W2028697269 modified "2023-09-25" @default.
• W2028697269 title "A Phase I Study of Capecitabine in Combination with Vinorelbine in Advanced Breast Cancer" @default.
• W2028697269 cites W1579641819 @default.
• W2028697269 cites W1755746957 @default.
• W2028697269 cites W1811085086 @default.
• W2028697269 cites W1828283074 @default.
• W2028697269 cites W1843618725 @default.
• W2028697269 cites W1849818006 @default.
• W2028697269 cites W1923449517 @default.
• W2028697269 cites W1939003096 @default.
• W2028697269 cites W1946638503 @default.
• W2028697269 cites W1970070403 @default.
• W2028697269 cites W1975402824 @default.
• W2028697269 cites W2039176586 @default.
• W2028697269 cites W2099658604 @default.
• W2028697269 cites W2115727783 @default.
• W2028697269 cites W2123732467 @default.
• W2028697269 cites W2131770017 @default.
• W2028697269 cites W2143435580 @default.
• W2028697269 cites W2148809873 @default.
• W2028697269 cites W2167805334 @default.
• W2028697269 cites W2212225357 @default.
• W2028697269 cites W2267376886 @default.
• W2028697269 cites W2283947545 @default.
• W2028697269 cites W2293688022 @default.
• W2028697269 cites W2408050101 @default.
• W2028697269 cites W2414172943 @default.
• W2028697269 cites W2419122554 @default.
• W2028697269 doi "https://doi.org/10.3816/cbc.2003.n.019" @default.
• W2028697269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12864942" @default.
• W2028697269 hasPublicationYear "2003" @default.
• W2028697269 type Work @default.
• W2028697269 sameAs 2028697269 @default.
• W2028697269 citedByCount "20" @default.
• W2028697269 countsByYear W20286972692012 @default.
• W2028697269 countsByYear W20286972692015 @default.
• W2028697269 countsByYear W20286972692016 @default.
• W2028697269 countsByYear W20286972692019 @default.
• W2028697269 crossrefType "journal-article" @default.
• W2028697269 hasAuthorship W2028697269A5041259750 @default.
• W2028697269 hasAuthorship W2028697269A5051722602 @default.
• W2028697269 hasAuthorship W2028697269A5057828080 @default.
• W2028697269 hasAuthorship W2028697269A5059974723 @default.
• W2028697269 hasAuthorship W2028697269A5065513710 @default.
• W2028697269 hasAuthorship W2028697269A5086984759 @default.
• W2028697269 hasAuthorship W2028697269A5090055323 @default.
• W2028697269 hasConcept C121608353 @default.
• W2028697269 hasConcept C126322002 @default.
• W2028697269 hasConcept C141071460 @default.
• W2028697269 hasConcept C143998085 @default.
• W2028697269 hasConcept C2775930923 @default.
• W2028697269 hasConcept C2776694085 @default.
• W2028697269 hasConcept C2777063308 @default.
• W2028697269 hasConcept C2777909004 @default.
• W2028697269 hasConcept C2778239845 @default.
• W2028697269 hasConcept C2778496288 @default.
• W2028697269 hasConcept C2780350996 @default.
• W2028697269 hasConcept C2781413609 @default.
• W2028697269 hasConcept C526805850 @default.
• W2028697269 hasConcept C530470458 @default.
• W2028697269 hasConcept C71924100 @default.
• W2028697269 hasConcept C90924648 @default.
• W2028697269 hasConceptScore W2028697269C121608353 @default.
• W2028697269 hasConceptScore W2028697269C126322002 @default.
• W2028697269 hasConceptScore W2028697269C141071460 @default.
• W2028697269 hasConceptScore W2028697269C143998085 @default.
• W2028697269 hasConceptScore W2028697269C2775930923 @default.
• W2028697269 hasConceptScore W2028697269C2776694085 @default.
• W2028697269 hasConceptScore W2028697269C2777063308 @default.
• W2028697269 hasConceptScore W2028697269C2777909004 @default.
• W2028697269 hasConceptScore W2028697269C2778239845 @default.
• W2028697269 hasConceptScore W2028697269C2778496288 @default.
• W2028697269 hasConceptScore W2028697269C2780350996 @default.
• W2028697269 hasConceptScore W2028697269C2781413609 @default.
• W2028697269 hasConceptScore W2028697269C526805850 @default.
• W2028697269 hasConceptScore W2028697269C530470458 @default.
• W2028697269 hasConceptScore W2028697269C71924100 @default.
• W2028697269 hasConceptScore W2028697269C90924648 @default.
• W2028697269 hasLocation W20286972691 @default.
• W2028697269 hasLocation W20286972692 @default.
• W2028697269 hasOpenAccess W2028697269 @default.
• W2028697269 hasPrimaryLocation W20286972691 @default.
• W2028697269 hasRelatedWork W1966012540 @default.
• W2028697269 hasRelatedWork W1976067234 @default.
• W2028697269 hasRelatedWork W2025504439 @default.
• W2028697269 hasRelatedWork W2028697269 @default.
• W2028697269 hasRelatedWork W2039076282 @default.
• W2028697269 hasRelatedWork W2055603892 @default.
• W2028697269 hasRelatedWork W2056528636 @default.
• W2028697269 hasRelatedWork W2059561061 @default.

• next